Novofine Autocover Safety Needle Versus BD Safety Glide - Full Text View

Purpose

This study will examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.

Condition	Intervention	Phase
Health Personnel	Device: safety glide Device: autocover needle	Phase IV

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Crossover Assignment, Safety Study

Further study details as provided by Novo Nordisk:

Estimated Enrollment:	100
Study Start Date:	July 2005

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Hospital nurses with prior injection training without an infectious blood borne disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00121355

Locations


United States, Florida
	Novo Nordisk Clinical Trial Call Center
	Miami, Florida, United States, 33176

United States, Georgia
	Novo Nordisk Clinical Trial Call Center
	Atlanta, Georgia, United States, 30339

United States, Louisiana
	Novo Nordisk Clinical Trial Call Center
	New Orleans, Louisiana, United States, 70121

United States, Ohio
	Novo Nordisk Clinical Trial Call Center
	Cleveland, Ohio, United States, 44195
	Novo Nordisk Clinical Trial Call Center
	Portsmouth, Ohio, United States, 45662
	Novo Nordisk Clinical Trial Call Center
	Zanesville, Ohio, United States, 43701
	Novo Nordisk Clinical Trial Call Center
	Westerville, Ohio, United States, 43081

United States, Texas
	Novo Nordisk Clinical Trial Call Center
	Irving, Texas, United States, 75061
	Novo Nordisk Clinical Trial Call Center
	Houston, Texas, United States, 77030

Sponsors and Collaborators

Novo Nordisk

Investigators


Study Director:	Campbell Howard, MD	Novo Nordisk

More Information

Study ID Numbers:	MS241-1674
First Received:	July 13, 2005
Last Updated:	June 14, 2007
ClinicalTrials.gov Identifier:	NCT00121355
Health Authority:	United States: Institutional Review Board

Keywords provided by Novo Nordisk:

Needles

ClinicalTrials.gov processed this record on October 28, 2008

Sponsored by:	Novo Nordisk
Information provided by:	Novo Nordisk
ClinicalTrials.gov Identifier:	NCT00121355